Cargando…

Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck

EGFR activation induces cell proliferation, neoformation of blood vessels, survival, and metastasis of the cancer cells. Nimotuzumab is an engineered, intermediate affinity anti-EGFR antibody, that apart from other drugs in its class, is very safe and does not cause hypomagnesemia or grade 3–4 cutan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crombet Ramos, Tania, Mestre Fernández, Braulio, Mazorra Herrera, Zaima, Iznaga Escobar, Normando E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266975/ https://www.ncbi.nlm.nih.gov/pubmed/32537431 http://dx.doi.org/10.3389/fonc.2020.00817

Ejemplares similares

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
por: Mazorra, Zaima, et al.
Publicado: (2017)

Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Thai Hoa, Nguyen Thi, et al.
Publicado: (2020)

Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin
por: González Fernández, Sandra, et al.
Publicado: (2022)

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
por: Wu, Qiuji, et al.
Publicado: (2021)

Stereotactic Body Radiotherapy as Primary Treatment for Elderly Patients with Medically Inoperable Head and Neck Cancer
por: Vargo, John A., et al.
Publicado: (2014)

EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects
por: Perez, Rolando, et al.
Publicado: (2011)

Nimotuzumab for COVID-19: case series
por: Abdo Cuza, Anselmo A, et al.
Publicado: (2021)

Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy
por: Suárez, Gisela María, et al.
Publicado: (2022)

Immunosenescence and gender: a study in healthy Cubans
por: García Verdecia, Beatriz, et al.
Publicado: (2013)

Nimotuzumab with intensity-modulated radiation therapy in unresectable and platinum-ineligible locally advanced head-and-neck cancer
por: Srinivas, K. Satish, et al.
Publicado: (2020)

Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: A meta-analysis of randomized controlled trials
por: Yuan, Yan, et al.
Publicado: (2022)

Addition of Nimotuzumab to Standard TPF Regimen in Locally Advanced Head and Neck Cancer: A Single Institutional Study
por: Koramati, Samuel Luke, et al.
Publicado: (2021)

Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial
por: Yuan, Jing-Jing, et al.
Publicado: (2022)

The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer
por: Crombet Ramos, Tania, et al.
Publicado: (2021)

Efficacy and survival analysis of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma
por: Wang, Lili, et al.
Publicado: (2023)

Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment
por: Londres, Henrry Diaz, et al.
Publicado: (2022)

Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report
por: Li, Yan, et al.
Publicado: (2022)

Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule
por: Popa, Xitlally, et al.
Publicado: (2020)

Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario
por: Diaz, Henrry, et al.
Publicado: (2022)

Editorial: Head and neck cancer in the elderly
por: Szturz, Petr, et al.
Publicado: (2023)

Image cytometric nuclear texture features in inoperable head and neck cancer: a pilot study
por: Strojan-Flezar, Margareta, et al.
Publicado: (2011)

Hypofractionated Palliative Radiotherapy in Locally Advanced Inoperable Head and Neck Cancer: CMC Vellore Experience
por: Das, Saikat, et al.
Publicado: (2013)

A retrospective study on unresectable or inoperable head and neck cancers treated with stereotactic ablative brachytherapy
por: Zhao, Genghao, et al.
Publicado: (2022)

Induction Chemotherapy and Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy for Inoperable Pancreas Cancer
por: Chuong, Michael D., et al.
Publicado: (2022)

Inequality in the Survival of Patients With Head and Neck Cancer in Scotland
por: Ingarfield, Kate, et al.
Publicado: (2019)

Descriptive epidemiology of the head and neck cancers in old patients
por: Gatta, Gemma, et al.
Publicado: (2023)

Novel Diagnostic Approaches for Assessment of the Clinically Negative Neck in Head and Neck Cancer Patients
por: Driessen, Daphne A. J. J., et al.
Publicado: (2021)

Editorial: Immunology and Immunotherapy of Head and Neck Cancer
por: Gavrielatou, Niki, et al.
Publicado: (2021)

Editorial: Women in head and neck cancer 2021
por: Economopoulou, Panagiota, et al.
Publicado: (2022)

Editorial: Insights in head and neck cancer: 2021
por: Lybaert, Willem, et al.
Publicado: (2023)

Lipid metabolism reprogramming in head and neck cancer
por: Liang, Jinfeng, et al.
Publicado: (2023)

Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer
por: Saiz-Ladera, Cristina, et al.
Publicado: (2021)

Nimotuzumab Combined With Irradiation Enhances the Inhibition to the HPV16 E6-Promoted Growth of Cervical Squamous Cell Carcinoma
por: Xu, Zhonghua, et al.
Publicado: (2020)

Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing
por: Sun, Dantong, et al.
Publicado: (2020)

The Application of Nimotuzumab Combined With Definitive Chemoradiotherapy Toward the Treatment of Locally Advanced Cervical Esophageal Carcinoma: A Retrospective Study
por: Hu, Jing, et al.
Publicado: (2022)

Inoperable or incompletely resected craniofacial osteosarcoma treated by particle radiotherapy
por: Seidensaal, Katharina, et al.
Publicado: (2022)

Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
por: Evans, Rachel, et al.
Publicado: (2022)

Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group
por: Klinghammer, Konrad, et al.
Publicado: (2022)

PET/CT in Radiotherapy Planning for Head and Neck Cancer
por: Newbold, Katie, et al.
Publicado: (2012)

Editorial: Advances in Head and Neck Cancer Immunology and Immunotherapy
por: Abu Eid, Rasha
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0ode59ut1k625a4tvimfb9k06b